Global market valuation was derived through revenue mapping and procedure volume analysis across dental therapeutic devices and pharmaceutical interventions. The methodology included:
• The identification of over 40 key manufacturers in North America, Europe, Asia-Pacific, and Latin America who specialize in the production of custom and prefabricated occlusal splints, mandibular advancement devices, botulinum toxin formulations, muscle relaxants, and sleep monitoring technologies.
• Product mapping across oral appliance therapy (hard/soft splints, stabilization splints, repositioning appliances), pharmacological segments (botulinum toxin type A, benzodiazepines, muscle relaxants), behavioral therapy platforms, and diagnostic devices (home sleep apnea tests, polysomnography equipment used in bruxism diagnosis)
• Analysis of reported and modeled annual revenues specific to nocturnal bruxism treatment portfolios, including dental laboratory service revenues associated with device fabrication
• Coverage of manufacturers representing 72-77% of global market share in 2024
• Extrapolation using bottom-up (procedure volume × ASP by country for sleep studies, splint fittings, and Botox injections) and top-down (manufacturer revenue validation and pharmaceutical prescription data analysis) approaches to derive segment-specific valuations for reversible versus irreversible treatment modalities